# Inquis Medical

> Inquis Medical is a privately funded medical device company founded in 2020 and headquartered in
> Menlo Park, California, dedicated to advancing the treatment of venous thromboembolic disease (VTE).
> Its AVENTUS Precision Thrombectomy System is a single-catheter mechanical thrombectomy platform
> combining a directional intelligent tip, an integrated 5F navigation catheter and dilator, TrueClot
> real-time tissue sensing at the catheter tip, and in-line filtration with autologous blood
> reinfusion — with no capital equipment. Inquis Medical publishes no public developer program and no
> machine-readable API contract.

Generated by the API Evangelist enrichment pipeline on 2026-08-23.
method: generated
source: apis.yml + probed public pages on inquismedical.com

## API surface

Inquis Medical has no public API. As of 2026-08-23 there is no developer portal, no API reference, no
OpenAPI/Swagger/AsyncAPI/GraphQL/MCP contract, and no `api.`, `developer.`, `docs.`, `dev.`, `app.`,
`portal.` or `partners.` hostname resolving on the inquismedical.com domain (all NXDOMAIN). Contract
discovery was run against the one host the company operates: `/openapi.json`, `/openapi.yaml`,
`/swagger.json`, `/v1/openapi.json`, `/api-docs`, `/docs`, `/redoc` and `/graphql` all return the
WordPress theme 404 page; `/llms.txt` and `/.well-known/security.txt` return a real nginx 404; the
whole `/.well-known/` directory — including `agent-card.json` and `agent.json` — is answered by a 403
WAF interstitial, so there is no A2A agent card. No SOAP `?wsdl` surface exists. No first-party SDK or
client library is published on npm, PyPI, or any other registry.

The company's product is clinical hardware — a catheter system used at the point of care by
interventional physicians — so the absence of an API is a fact about what Inquis Medical sells, not a
gap in its engineering. The only machine-readable JSON served from inquismedical.com is the stock
WordPress core REST API at `/wp-json/` (namespace `wp/v2` and plugin namespaces), which is the
marketing site's CMS discovery document, not an Inquis Medical product API, and is deliberately not
catalogued as one.

Inquis Medical does operate a public GitHub organization, `InquisMedical`, created in October 2022. It
contains a single repository, `SPI_DMA` ("SPI with DMA", embedded firmware), which is empty — zero
bytes, no commits with content since May 2023.

## Company

- [Inquis Medical](https://inquismedical.com/): Company website.
- [About](https://inquismedical.com/about-us/): Company background, mission, and founding.
- [Our Team](https://inquismedical.com/our-team/): Leadership — co-founders and Co-CEOs Vahid Saadat and Mojgan Saadat.
- [News & Articles](https://inquismedical.com/about-us/news/): Press releases and announcements.
- [News RSS](https://inquismedical.com/feed/): Machine-readable feed of the newsroom.
- [Careers](https://inquismedical.com/careers/): Open roles.
- [Contact](https://inquismedical.com/contact-us/): Contact form, info@inquismedical.com, 888-526-7738 — the only published support channels.
- [GitHub organization](https://github.com/InquisMedical): One empty embedded-firmware repository.

## Technology and products

- [Technologies](https://inquismedical.com/technology/): AVENTUS Thrombectomy System — intelligent tip design, TrueClot sensing, integrated blood return.
- [AVENTUS Introducer Sheath](https://inquismedical.com/introducer-sheath/): Conduit for endovascular device insertion, designed to minimize associated blood loss.
- [Clinical Evidence](https://inquismedical.com/clinical-evidence/): AVENTUS IDE pivotal trial results and published data.
- [Patients & Caregivers — About VTE](https://inquismedical.com/for-patients-caregivers/): Patient-facing education on venous thromboembolism.
- [FAQs](https://inquismedical.com/faqs/): Frequently asked questions.
- [Patents](https://inquismedical.com/patents/): Patent listing.

## Regulatory status

- FDA 510(k) clearance for peripheral indications (non-surgical removal of emboli and thrombi from blood vessels).
- FDA 510(k) clearance for the treatment of pulmonary embolism, announced June 2025.
- AVENTUS Clot Management System indicated for use with the AVENTUS Thrombectomy System for autologous blood transfusion.

## Funding

- $40 million Series B, announced November 2024.
- $75 million Series C, to scale commercial adoption of the AVENTUS Thrombectomy System.
- [Secondary market listing](https://forgeglobal.com/inquis-medical_stock/): Forge Global private-share page.

## Policies

- [Terms & Conditions](https://inquismedical.com/terms-and-conditions/)

Inquis Medical publishes no privacy policy page at a discoverable URL; `/privacy-policy/` returns 403.

## API Evangelist artifacts in this repository

- [security/inquis-medical-domain-security.yml](security/inquis-medical-domain-security.yml): Probed TLS, HSTS, DNSSEC, CAA, SPF and DMARC posture for inquismedical.com.
- [well-known/inquis-medical-well-known.yml](well-known/inquis-medical-well-known.yml): Probed `/.well-known/` results — a measured absence, every path 404 or 403.
- [apis.yml](apis.yml): APIs.json 0.23 profile of the company.